The technical and diagnostic performance of the Amerlite-MAB'TM enhanced luminescence assay for free thyroxine (FT4) was assessed in a multicenter evaluation trial. The euthyroid central 95% reference range for Fr, (1393sub-jects) was 11.5-27.7 pmol/L (by cumulative frequency plot with two-tailed 2.5% cutoffs). Results (y) agreed with those of similar radioactive method (Amerlex-MAB4T" Fr4) (x): y = 1.06 x + 0.54, S,,,, = 335.5, n = 235). Mean within-assay precision (CV) in six centers was 5.7% at 6 pmol/L and 2.6% at 51 pmol/L Fr4; between-assay precision (CV) was 7.2% and 3.6%, respectively. Diagnostic performance was assessed in all patient groups usually encountered, includingthose with nonthyroidalillness and extreme binding-protein anomalies. In elderly euthyroid subjects, the proportion of above-normal FT4 values exceeded that in younger age-groups. These increases often accompanied normal estimates of thyrotropin and, in some cases, might have arisen by interference from medication that is taken more often by the elderly. antibody assay, because it contains no extra albumin to bind T4, responds to serum dilution as expected on theoretical grounds (3, 7-10).
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We report a multicenter trial of the Amerlite-MAB" FF4 immunoassay, giving special attention to circumstances in which endogenous T4 binding is thought to be disturbed (11-16).
Materials and Methods Trial Design
Six centers (three from the UK, two from Germany, and one from Sweden) entered the trial on behalf 
Technical Studies
In each assay, the first 12 wells contained duplicates of six calibrators (nominal values 0, 6, 13, 26, 60, and 100 pmoL'L). Three control sera (Amerlite Free Thyroid Hormone controls, nominal FT4 values 5.5, 17, and 50 pmolIL) were also measured in duplicate in each assay, as were five in-house control sera specially supplied for the trial [nominal FT4 4.5, 16.5, 40, 90, and (pregnancy serum control) 18 pmolIL]. Unknown (patients') specimens were measured in duplicate in the remaining wells.
Within-assay precision, drift, and sensitivity were assessed by including both the lowest-concentration calibrator (0 pmolIL FT4), the Amerlite Free Thyroid Hormone controls, and in-house controls throughout an assay plate in a predetermined pattern: 10 duplicates of the lowest calibrator and 4 duplicates each of the Free Thyroid Hormone and in-house controls.
Assay drift was estimated by regression of individual control values against well number over a standard assay (96 wells). The assay detection limit was calculated from 20 measurements by each participant of the zero FF4 calibrator. The mean -2 SD value of the zero calibrator light signal, interpolated to FT4 concentration, represented the detection limit of the assay. The mean limit from all participants was calculated as the root mean square (RMS) value.
Within-assay precision was measured by taking the mean CV obtained by each participant for each of the control sera from the assays specially dedicated to this study. Each participant calculated between-assay precision from the data for each control in eight assays. Precision overall was derived from the RMS value of the individual center's estimates. Blood samples were taken and the sera separated and stored at -20#{176}C, according to each center's specific protocol. Other specially selected stored samples were also used by each center.
Patients'

Methods
FT4.
The protocol for the Amerlite-MAB FT4 assay is described elsewhere (17). The centers also measured VT4, T4, and thyrotropin by using established methods.
Because each center's central 95% reference range for FT4 was similar, even by different methods, we could amalgamate the results. In addition, for each patient group, the mean, range, and spread of FT4 values by the Amerlite kit were compared between those determined by the centers taking part in the trial directly and those in the sera analyzed by the manufacturer.
In all cases, the results were so similar that we could combine them.
Thyroxine-binding globulin (TBG The corresponding between-assay RMS CVs for the same controls were: 9.5%, 7.4%, 4.2%, 5.4%, 4.8%, 3.3%, 3.6%, and 3.3%, respectively.
Results
Analytical Assessment
Drift. Assay drift, calculated from the percentage change between controls measured at the beginning and again at the end of a full plate assay, varied from -2.1% to -5.7% for all controls, based on 12 determinations from the six centers.
Detection limit. The overall RMS mean detection limit for FT4 was 0.73 pmol/L (95% confidence range 0.34-
pmol/L).
Clinical Assessment
Central 95% euthyroid reference range. For 570 euthyroid subjects measured by the six external centers in the trial, the central 95% euthyroid In Table 1 The means and 95% reference ranges (Iogxtransforrnation) are as shown in Table 1 .
The assay's ability to discriminate overt hypothyroid and hyperthyroid sera from the lower and upper limits of the central 95% reference range was investigated with samples from 220 hypothyroid, 224 hyperthyroid, and 1393 euthyroid subjects (total n = 1837).
Four of 224 (1.8%) of hyperthyroid values (overall mean 61.5 pmol/L) and 8 of 220 (3.6%) of hypothyroid values (overall mean 6.7 pmol/L) lay within the central 95% reference range, calculated from the 2.5% and 97.5% cumulative frequency cutoffs (11.5-27.7 pmoIIL) (Fig. 1) of pregnancy from apparently healthy euthyroid subjects (Fig. 4) . For 84 subjects in the first trimester, the data (Fig. 4A) (Fig. 4B) were (mean, log,x transform) 13.2 pmol/L (95% range 9.4-18.5 pmol/L), 78% of the euthyroid central 95% reference mean. No values lay above the euthyroid reference range, but 9 of 131 (6.9%) lay below.
For 128 subjects in the third trimester (Fig. 4C) Familial dysalbuminemic hyperthyroxinemia (FDH). Serum from 10 apparently euthyroid subjects with FDH had a mean FT4 value of 12.4 pmol/L, 26% below the euthyroid reference mean. Three of the 10 values lay below the reference range; however, none was above the range, in contrast to the results with many analog tracer FT4 assays. These results resemble those found by using equilibrium dialysis (29). Antithyroid hormone autoantibodies. Seven samples contained high concentrations of anti-T4 (or T3) autoantibodies (these affect analog tracer assays severely). Two of these subjects were considered euthyroid (normal thyrotropin), two hypothyroid (increased thyrotropin), and three euthyroid taking oral T4 therapy (normal or suppressed thyrotropin). FT4 values were: 15.5 and 17.1 pmoIIL, euthyroid; 9.7 and 11.9 pmolIL, hypothyroid; 27.6, 22.8, and 23.9 pmol/L, euthyroid on T4 therapy. All values resembled those from similar subjects with no autoantibodies.
In this, the assay agrees with the radiolabled A1nerlexMAB* FT4 method (1).
DIscussIon
The Ainerlite-MAB FT4 assay was evaluated to assess how it discriminated thyroid dysfunction and assigned subjects with highly abnormal concentrations or binding affinities of serum T4-binding proteins to appropriate diagnostic regions. Because the assay buffers lack albumin, it was necessary to examine circumstances in which other substances might displace T4 from the serum binding proteins. For example, subjects with severe NTI (11-16) could be taking drugs temporarily promot-ing T4 displacement
